Understanding cardiovascular risk in rheumatoid arthritis: Still a long way to go

Atherosclerosis. 2017 Jan:256:123-124. doi: 10.1016/j.atherosclerosis.2016.11.009. Epub 2016 Nov 17.

Author

Roberta Gualtierotti¹

Affiliation

¹ Department of Clinical Sciences and Community Health, University of Milan, Division of Rheumatology, Lupus Clinic, G. Pini Institute, P.za Cardinal Ferrari 1, 20122 Milano, Italy. Electronic address: roberta.gualtierotti@unimi.it.

PMID: 27993384
DOI: 10.1016/j.atherosclerosis.2016.11.009

No abstract available

Keywords: Cardiovascular risk; IL-6 blockade; Rheumatoid arthritis; Tocilizumab.

Publication types

Editorial
Comment

MeSH terms

Arthritis, Rheumatoid*
Cardiovascular Diseases*
Humans
Natriuretic Peptide, Brain
Peptide Fragments
Receptors, Interleukin-6
Risk Factors
Troponin T

Substances

Peptide Fragments
Receptors, Interleukin-6
Troponin T
pro-brain natriuretic peptide (1-76)
Natriuretic Peptide, Brain